Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in CLL, SLL, Richter's Syndrome, and Prolymphocytic Leukemia
NCT02029443Phase 2Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Jan 2014
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of acalabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter's syndrome (RS), prolymphocytic leukemia (PLL), sponsored by Acerta Pharma. Started Jan 2014; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter's syndrome (RS)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT02029443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029443.